{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:25:54Z","timestamp":1772119554455,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10637-021-01199-y","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T08:02:48Z","timestamp":1637222568000},"page":"420-429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0744-7425","authenticated-orcid":false,"given":"Hisanaga","family":"Nomura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Daiko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Demachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikatsu","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"issue":"1","key":"1199_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD (2019) Jemal A (2019) Cancer statistics. CA Cancer J Clin 69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"1199_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","volume":"12","author":"KM Sjoquist","year":"2011","unstructured":"Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V, Australasian Gastro-Intestinal Trials G (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12(7):681\u2013692. https:\/\/doi.org\/10.1016\/S1470-2045(11)70142-5","journal-title":"Lancet Oncol"},{"key":"1199_CR3","doi-asserted-by":"publisher","unstructured":"Kidane B, Coughlin S, Vogt K, Malthaner R (2015) Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev (5):CD001556. https:\/\/doi.org\/10.1002\/14651858.CD001556.pub3","DOI":"10.1002\/14651858.CD001556.pub3"},{"issue":"3","key":"1199_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1470-2045(07)70039-6","volume":"8","author":"V Gebski","year":"2007","unstructured":"Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J, Australasian Gastro-Intestinal Trials G (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8(3):226\u2013234. https:\/\/doi.org\/10.1016\/S1470-2045(07)70039-6","journal-title":"Lancet Oncol"},{"issue":"1","key":"1199_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","volume":"19","author":"N Ando","year":"2012","unstructured":"Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, Ikeda K, Kanda T, Tsujinaka T, Nakamura K, Fukuda H (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19(1):68\u201374. https:\/\/doi.org\/10.1245\/s10434-011-2049-9","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"1199_CR6","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/cas.12274","volume":"104","author":"H Hara","year":"2013","unstructured":"Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, Tanaka Y, Hamamoto Y, Matsushita H, Nagase M, Hosoya Y (2013) Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci 104(11):1455\u20131460. https:\/\/doi.org\/10.1111\/cas.12274","journal-title":"Cancer Sci"},{"issue":"7","key":"1199_CR7","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1093\/jjco\/hyt061","volume":"43","author":"Nakamura K, Kato K, Igaki H, Ito Y, Mizusawa J, Ando N, Udagawa H, Tsubosa Y, Daiko H, Hironaka S, Fukuda H, Kitagawa Y, Japan Esophageal Oncology Group\/Japan Clinical Oncology G","year":"2013","unstructured":"Nakamura K, Kato K, Igaki H, Ito Y, Mizusawa J, Ando N, Udagawa H, Tsubosa Y, Daiko H, Hironaka S, Fukuda H, Kitagawa Y, Japan Esophageal Oncology Group\/Japan Clinical Oncology G (2013) Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol 43(7):752\u2013755. https:\/\/doi.org\/10.1093\/jjco\/hyt061","journal-title":"Jpn J Clin Oncol"},{"issue":"9","key":"1199_CR8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(05)70255-2","volume":"6","author":"M Di Maio","year":"2005","unstructured":"Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, Manzione L, Illiano A, Barbera S, Robbiati SF, Frontini L, Piazza E, Ianniello GP, Veltri E, Castiglione F, Rosetti F, Gebbia V, Seymour L, Chiodini P, Perrone F (2005) Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6(9):669\u2013677. https:\/\/doi.org\/10.1016\/S1470-2045(05)70255-2","journal-title":"Lancet Oncol"},{"issue":"2","key":"1199_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/bjc.1997.49","volume":"75","author":"T Saarto","year":"1997","unstructured":"Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75(2):301\u2013305. https:\/\/doi.org\/10.1038\/bjc.1997.49","journal-title":"Br J Cancer"},{"issue":"10","key":"1199_CR10","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1038\/sj.bjc.6601366","volume":"89","author":"DA Cameron","year":"2003","unstructured":"Cameron DA, Massie C, Kerr G, Leonard RC (2003) Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89(10):1837\u20131842. https:\/\/doi.org\/10.1038\/sj.bjc.6601366","journal-title":"Br J Cancer"},{"issue":"7","key":"1199_CR11","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/sj.bjc.6602783","volume":"93","author":"B Schuell","year":"2005","unstructured":"Schuell B, Gruenberger T, Kornek GV, Dworan N, Depisch D, Lang F, Schneeweiss B, Scheithauer W (2005) Side effects during chemotherapy predict tumour response in advanced colorectal cancer. Br J Cancer 93(7):744\u2013748. https:\/\/doi.org\/10.1038\/sj.bjc.6602783","journal-title":"Br J Cancer"},{"issue":"1","key":"1199_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/sj.bjc.6603831","volume":"97","author":"T Yamanaka","year":"2007","unstructured":"Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M (2007) Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. Br J Cancer 97(1):37\u201342. https:\/\/doi.org\/10.1038\/sj.bjc.6603831","journal-title":"Br J Cancer"},{"issue":"8","key":"1199_CR13","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00228-017-2260-0","volume":"73","author":"A Otake","year":"2017","unstructured":"Otake A, Tsuji D, Taku K, Kawasaki Y, Yokoi M, Nakamori H, Osada M, Matsumoto M, Inoue K, Hirai K, Itoh K (2017) Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine. Eur J Clin Pharmacol 73(8):1033\u20131039. https:\/\/doi.org\/10.1007\/s00228-017-2260-0","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"1199_CR14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1177\/1060028019830785","volume":"53","author":"K Yamamoto","year":"2019","unstructured":"Yamamoto K, Sasano T, Tsuji D, Ishizuka Y, Tokou U, Nakamichi H, Yoneda T, Shiokawa M, Yabe K (2019) Effects of Chemotherapy-Induced Neutropenia on Overall Survival in Patients With Unresectable or Metastatic Urothelial Carcinoma to Gemcitabine Plus Cisplatin Combination Chemotherapy. Ann Pharmacother 53(7):690\u2013696. https:\/\/doi.org\/10.1177\/1060028019830785","journal-title":"Ann Pharmacother"},{"issue":"1","key":"1199_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10147-015-0875-7","volume":"21","author":"H Konishi","year":"2016","unstructured":"Konishi H, Fujiwara H, Shiozaki A, Hiramoto H, Kosuga T, Komatsu S, Ichikawa D, Okamoto K, Otsuji E (2016) Effects of neutropenia and histological responses in esophageal squamous cell carcinoma with neo-adjuvant chemotherapy. Int J Clin Oncol 21(1):95\u2013101. https:\/\/doi.org\/10.1007\/s10147-015-0875-7","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"1199_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00280-020-04118-9","volume":"86","author":"H Nomura","year":"2020","unstructured":"Nomura H, Tsuji D, Demachi K, Mochizuki N, Matsuzawa H, Yano T, Daiko H, Fujii S, Kojima T, Itoh K, Kawasaki T (2020) ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. Cancer Chemother Pharmacol 86(2):315\u2013324. https:\/\/doi.org\/10.1007\/s00280-020-04118-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"1199_CR17","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","volume":"14","author":"LP Martin","year":"2008","unstructured":"Martin LP, Hamilton TC, Schilder RJ (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14(5):1291\u20131295. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-2238","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1199_CR18","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1007\/s13277-013-1493-5","volume":"35","author":"Y Yang","year":"2014","unstructured":"Yang Y, Xian L (2014) The association between the ERCC1\/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour Biol 35(4):2905\u20132921. https:\/\/doi.org\/10.1007\/s13277-013-1493-5","journal-title":"Tumour Biol"},{"key":"1199_CR19","doi-asserted-by":"publisher","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","DOI":"10.1016\/j.ejca.2008.10.026"},{"issue":"16","key":"1199_CR20","doi-asserted-by":"publisher","first-page":"5881","DOI":"10.1002\/cam4.3273","volume":"9","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Zhang Y, Wang X, Geng X, Zhu L, Li M (2020) Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy. Cancer Med 9(16):5881\u20135888. https:\/\/doi.org\/10.1002\/cam4.3273","journal-title":"Cancer Med"},{"issue":"4","key":"1199_CR21","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00520-019-05001-x","volume":"28","author":"H Nomura","year":"2020","unstructured":"Nomura H, Hatogai K, Maki Y, Mochizuki N, Tanaka M, Saito S, Daiko H, Kojima T, Kawasaki T (2020) Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer. Support Care Cancer 28(4):1849\u20131854. https:\/\/doi.org\/10.1007\/s00520-019-05001-x","journal-title":"Support Care Cancer"},{"issue":"1","key":"1199_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s10147-011-0349-5","volume":"18","author":"R Yano","year":"2013","unstructured":"Yano R, Konno A, Watanabe K, Tsukamoto H, Kayano Y, Ohnaka H, Goto N, Nakamura T, Masada M (2013) Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials. Int J Clin Oncol 18(1):96\u2013104. https:\/\/doi.org\/10.1007\/s10147-011-0349-5","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"1199_CR23","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1111\/cas.12820","volume":"106","author":"J Cheng","year":"2015","unstructured":"Cheng J, Liu W, Zeng X, Zhang B, Guo Y, Qiu M, Jiang C, Wang H, Wu Z, Meng M, Zhuang H, Zhao L, Hao J, Cai Q, Xie D, Pang Q, Wang P, Yuan Z, Qian D (2015) XRCC3 is a promising target to improve the radiotherapy effect of esophageal squamous cell carcinoma. Cancer Sci 106(12):1678\u20131686. https:\/\/doi.org\/10.1111\/cas.12820","journal-title":"Cancer Sci"},{"issue":"4","key":"1199_CR24","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/annonc\/mdj135","volume":"17","author":"de las Penas R, Sanchez-Ronco M, Al","year":"2006","unstructured":"de las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, Massuti B, Queralt C, Botia M, Garcia-Gomez R, Isla D, Cobo M, Santarpia M, Cecere F, Mendez P, Sanchez JJ, Rosell R, Spanish Lung Cancer G, (2006) Polymorphisms in DNA repair genes modulate survival in cisplatin\/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17(4):668\u2013675. https:\/\/doi.org\/10.1093\/annonc\/mdj135","journal-title":"Ann Oncol"},{"issue":"1","key":"1199_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5306\/wjco.v4.i1.14","volume":"4","author":"J Assis","year":"2013","unstructured":"Assis J, Pereira D, Medeiros R (2013) Ovarian cancer and DNA repair: DNA ligase IV as a potential key. World J Clin Oncol 4(1):14\u201324. https:\/\/doi.org\/10.5306\/wjco.v4.i1.14","journal-title":"World J Clin Oncol"},{"issue":"2","key":"1199_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1124\/jpet.105.084053","volume":"314","author":"ZY Xu","year":"2005","unstructured":"Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R (2005) Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther 314(2):495\u2013505. https:\/\/doi.org\/10.1124\/jpet.105.084053","journal-title":"J Pharmacol Exp Ther"},{"issue":"23","key":"1199_CR27","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1038\/sj.onc.1203578","volume":"19","author":"H Maacke","year":"2000","unstructured":"Maacke H, Jost K, Opitz S, Miska S, Yuan Y, Hasselbach L, Luttges J, Kalthoff H, Sturzbecher HW (2000) DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 19(23):2791\u20132795. https:\/\/doi.org\/10.1038\/sj.onc.1203578","journal-title":"Oncogene"},{"issue":"3","key":"1199_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.radonc.2012.09.013","volume":"105","author":"L Fachal","year":"2012","unstructured":"Fachal L, Gomez-Caamano A, Peleteiro P, Carballo A, Calvo-Crespo P, Sanchez-Garcia M, Lobato-Busto R, Carracedo A, Vega A (2012) Association of a XRCC3 polymorphism and rectum mean dose with the risk of acute radio-induced gastrointestinal toxicity in prostate cancer patients. Radiother Oncol 105(3):321\u2013328. https:\/\/doi.org\/10.1016\/j.radonc.2012.09.013","journal-title":"Radiother Oncol"},{"issue":"1","key":"1199_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1667\/RR1219.1","volume":"170","author":"RJ Burri","year":"2008","unstructured":"Burri RJ, Stock RG, Cesaretti JA, Atencio DP, Peters S, Peters CA, Fan G, Stone NN, Ostrer H, Rosenstein BS (2008) Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res 170(1):49\u201359. https:\/\/doi.org\/10.1667\/RR1219.1","journal-title":"Radiat Res"},{"issue":"4","key":"1199_CR30","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s10637-021-01075-9","volume":"39","author":"F Pasqualetti","year":"2021","unstructured":"Pasqualetti F, Gonnelli A, Orlandi P, Palladino E, Giannini N, Gadducci G, Mattioni R, Montrone S, Calistri E, Mazzanti CM, Franceschi S, Ortenzi V, Scatena C, Zavaglia K, Fanelli GN, Morganti R, Santonocito O, Bocci G, Naccarato GA, Paiar F (2021) Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy. Invest New Drugs 39(4):1159\u20131165. https:\/\/doi.org\/10.1007\/s10637-021-01075-9","journal-title":"Invest New Drugs"},{"issue":"3","key":"1199_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/tpj.2015.46","volume":"16","author":"LE Salnikova","year":"2016","unstructured":"Salnikova LE, Kolobkov DS (2016) Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis. Pharmacogenomics J 16(3):249\u2013265. https:\/\/doi.org\/10.1038\/tpj.2015.46","journal-title":"Pharmacogenomics J"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01199-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01199-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01199-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T23:41:21Z","timestamp":1678491681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01199-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1199"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01199-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-967707\/v1","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"assertion":[{"value":"13 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional review board of the NCC, Japan in March 2017 (2016\u2013384). These patients were consented to be used the clinical information and DNA sample in the National Cancer Center (NCC) Biobank Registry. The study design is displayed on the website for the National Cancer Center Hospital East, providing the relatives of deceased patients the opportunity to decline participation in the current study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving Human Participants and\/or Animals"}},{"value":"All patients provided their written informed consent to allow the use of their clinical information and DNA samples, which are available in the NCC Biobank Registry.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Takashi Kojima received honoraria from Ono and MSD and research funding from Ono, MSD, Taiho, Chugai, Shionogi and Palexel. Tomoaki Yano received honoraria from Olympus, Meijiseika pharma and research funding from Olympus, Fujifirm, HOYA PENTAX, Rakuten Medical, SHIMADZU and Tokyo Giken. All other authors declare no potential conflicts of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of potential conflicts of interest"}}]}}